Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma

Hepatocellular carcinoma (HCC) responds poorly to conventional systemic therapies. The first-in-class proteasome inhibitor bortezomib has been approved in clinical use for hematologic malignancies and has shown modest activity in solid tumors, including HCC. However, a considerable proportion of pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Vandewynckel, Yves-Paul, Coucke, Céline, Laukens, Debby, Devisscher, Lindsey, Paridaens, Annelies, Bogaerts, Eliene, Vandierendonck, Astrid, Raevens, Sarah, Verhelst, Xavier, Van Steenkiste, Christophe, Libbrecht, Louis, Geerts, Anja, Van Vlierberghe, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085204/
https://www.ncbi.nlm.nih.gov/pubmed/27167000
http://dx.doi.org/10.18632/oncotarget.9222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085204/
https://www.ncbi.nlm.nih.gov/pubmed/27167000
http://dx.doi.org/10.18632/oncotarget.9222

Ejemplares similares